Blood Protein Atlas Maps 59 Diseases in Over 8,000 People
Scientists mapped 5,416 circulating proteins across 59 diseases, revealing shared and unique protein signatures that could transform precision medicine.
Summary
Researchers have created a pan-disease blood proteome atlas by profiling protein concentrations in 8,262 individuals across 59 diseases and healthy cohorts. Using up to 5,416 proteins per sample, the study identified proteins linked to age, sex, and BMI, as well as disease-specific signatures. The harmonized dataset reveals both shared and distinct protein patterns across diverse conditions, offering an unprecedented unified resource for understanding disease biology. Published in Science, this open-access atlas is designed to accelerate biomarker discovery and precision medicine research by allowing cross-disease protein comparisons within a single, standardized proteomics framework.
Detailed Summary
Understanding how the blood proteome shifts across dozens of diseases is a fundamental challenge in medicine. Circulating proteins reflect tissue states, immune activity, metabolism, and aging — making blood an ideal window into systemic health. Until now, most proteomic studies have examined single diseases in isolation, limiting cross-condition insights.
This landmark study from KTH Royal Institute of Technology and collaborators across Sweden, Turkey, and the UK profiled the circulating proteome of 8,262 individuals spanning 59 disease conditions and healthy control cohorts. Using proximity extension assay-based proteomics (Olink), researchers measured concentrations of up to 5,416 proteins per individual in a harmonized analytical pipeline.
Key findings show that many proteins vary predictably with age, sex, and BMI — essential covariates that must be accounted for in disease research. Beyond these baseline associations, the atlas reveals disease-specific protein signatures as well as proteins shared across multiple conditions, suggesting common inflammatory or metabolic pathways that cut across disease boundaries. This cross-disease comparison framework is a major advance over siloed studies.
For longevity research, the atlas is particularly powerful: it enables identification of proteins that track biological aging independently of specific disease states, potentially revealing novel aging biomarkers or therapeutic targets. Shared signatures across age-related diseases like cardiovascular disease, cancer, and neurodegeneration may point to common mechanisms worth targeting.
Caveats include that only the abstract was available for analysis, so specific disease-protein associations, statistical thresholds, and validation details cannot be fully assessed. The study is cross-sectional by design, limiting causal inference. Additionally, cohort heterogeneity across 59 disease groups may introduce confounding despite harmonization efforts.
Key Findings
- Blood proteomes of 8,262 individuals across 59 diseases were profiled using up to 5,416 proteins.
- Disease-specific protein signatures were identified alongside proteins shared across multiple conditions.
- Age, sex, and BMI were associated with distinct circulating protein patterns, critical covariates for disease research.
- A unified, harmonized proteomics dataset enables unprecedented cross-disease biological comparisons.
- The atlas is available as an open online resource to advance biomarker discovery and precision medicine.
Methodology
The study used proximity extension assay proteomics (Olink platform) to measure up to 5,416 proteins in blood samples from 8,262 individuals across 59 disease cohorts and healthy controls. All samples were processed within a harmonized analytical framework to enable cross-disease comparisons. Covariates including age, sex, and BMI were systematically assessed.
Study Limitations
Only the abstract was available, so specific statistical methods, effect sizes, and individual disease-protein associations cannot be independently verified. The cross-sectional design precludes causal conclusions about protein changes and disease progression. Cohort variability across 59 diverse disease groups may introduce unmeasured confounding despite harmonization efforts.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.